On August 5, Apotex filed a petition for an IPR on Patent No. 8,952,138, owned by Amgen. The ’138 patent is the same patent that is being challenged in the District Court for the Southern District of Florida, in a case in which the Federal Circuit affirmed a preliminary injunction enjoining Apotex from launching its biosimilar version of Amgen’s Neulasta. We have been covering the district court case extensively, most recently here.
We will continue to monitor and report on updates for IPR2016-01542.
